Leustatin (Cladribine)

Cladribine is a purine nucleoside analog that enters lymphocytes via nucleoside transporters. Inside the cell it is phosphorylated to an active triphosphate, which becomes incorporated into DNA during replication. This incorporation disrupts DNA synthesis and repair, triggering apoptosis of proliferating B‑ and T‑cells and providing immunosuppressive and antineoplastic effects.

The dosage of Leustatin is individualized by the prescribing physician based on the specific indication, patient weight, renal function, and overall clinical status. No standard dosing regimen is provided here; the prescriber determines the appropriate dose and schedule.

Safety data for cladribine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider before starting therapy.

To order Leustatin, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Leustatin (cladribine) belongs to the class of purine nucleoside analogs, offering oral or intravenous dosing that targets lymphocyte proliferation. Compared with other disease‑modifying therapies such as fingolimod or dimethyl fumarate, cladribine provides a shorter treatment course but carries a distinct safety profile, including a higher risk of lymphopenia and infections.

Leustatin should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Proper cold‑chain storage helps maintain drug stability and efficacy.

Leustatin is supplied as an intravenous solution and must be administered by a qualified healthcare professional. The infusion is given over a specified period according to the prescriber’s instructions, typically in a clinical setting where patient monitoring can be performed.

The most serious risks include severe lymphopenia leading to opportunistic infections, autoimmune hepatitis, and serious skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, liver dysfunction, and dermatologic changes throughout treatment.

Leustatin is contraindicated in patients with active severe infections, uncontrolled HIV, severe immunodeficiency, or known hypersensitivity to cladribine or any excipients. It should also be avoided in individuals with significant bone‑marrow failure unrelated to the target disease.